Literature DB >> 31810908

Establishment of Drug-resistant Cell Lines as a Model in Experimental Oncology: A Review.

Márcia Vanessa Sales Amaral1, Adrhyann Jullyanne DE Sousa Portilho2, Emerson Lucena DA Silva2, Lívia DE Oliveira Sales2, Jersey Heitor DA Silva Maués3, Maria Elisabete Amaral DE Moraes2, Caroline Aquino Moreira-Nunes4,2.   

Abstract

Many types of cancer are initially susceptible to chemotherapy, but during treatment, patients may develop resistance to therapy. Knowing that acquisition of drug resistance is a major clinical problem in antineoplastic treatment, the present work aimed to present, through a literature review, the development of chemoresistant cells lines as a model in experimental oncology. A total of 110 drug-resistant cell lines, mainly from lung tumors and leukemias, have been developed. In addition, it has been observed that the drugs used for induction of resistance represented the drugs used for first-line treatment of each neoplasia, since the ideal chemotherapeutic treatment to induce resistance in vitro aims at a better modulation of the therapeutic response in order to better study the mechanisms of resistance. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Cancer; cell lines; chemoresistance; experimental oncology; review

Year:  2019        PMID: 31810908     DOI: 10.21873/anticanres.13858

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Proteomic Analysis of the Non-genetic Response to Cisplatin in Lung Cancer Cells.

Authors:  Cristine DE Souza Dutra; Carolina Lumertz Martello; Nathan Araujo Cadore; Henrique Bunselmeyer Ferreira; Arnaldo Zaha; Karina Mariante Monteiro
Journal:  Cancer Diagn Progn       Date:  2021-07-03

2.  Single cell mass spectrometry studies reveal metabolomic features and potential mechanisms of drug-resistant cancer cell lines.

Authors:  Mei Sun; Xingxiu Chen; Zhibo Yang
Journal:  Anal Chim Acta       Date:  2022-04-01       Impact factor: 6.911

Review 3.  CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.

Authors:  Mostafa Vaghari-Tabari; Parisa Hassanpour; Fatemeh Sadeghsoltani; Faezeh Malakoti; Forough Alemi; Durdi Qujeq; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-06-17       Impact factor: 8.702

4.  NMS-873 Leads to Dysfunctional Glycometabolism in A p97-Independent Manner in HCT116 Colon Cancer Cells.

Authors:  Shan Li; Feng Wang; Gang Zhang; Tsui-Fen Chou
Journal:  Pharmaceutics       Date:  2022-03-31       Impact factor: 6.525

5.  Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein.

Authors:  Mariana Nunes; Patrícia M A Silva; Ricardo Coelho; Carla Pinto; Albina Resende; Hassan Bousbaa; Gabriela M Almeida; Sara Ricardo
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

Review 6.  Advanced Cellular Models for Preclinical Drug Testing: From 2D Cultures to Organ-on-a-Chip Technology.

Authors:  Valentina Foglizzo; Emiliano Cocco; Serena Marchiò
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

7.  FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells.

Authors:  George M Ramzy; Laura Boschung; Thibaud Koessler; Céline Delucinge-Vivier; Mylène Docquier; Thomas A McKee; Laura Rubbia-Brandt; Patrycja Nowak-Sliwinska
Journal:  Cancers (Basel)       Date:  2022-09-30       Impact factor: 6.575

8.  Modulated Electro-Hyperthermia Supports the Effect of Gemcitabine Both in Sensitive and Resistant Pancreas Adenocarcinoma Cell Lines.

Authors:  Gertrud Forika; Eva Kiss; Gabor Petovari; Titanilla Danko; Aron Bertram Gellert; Tibor Krenacs
Journal:  Pathol Oncol Res       Date:  2021-12-10       Impact factor: 3.201

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.